China Phytochemical Compounds Manufacturers & Suppliers

Unlike commercial traders who broker low-cost, unstandardized botanical powder, MedGence is a research-first natural medicine CRO/CDMO. We have over 14 years of research expertise, over 300 research scientists, and an empirical database built on 83 modernized classical TCM formulations and nearly 400 single-herb quality standards. We maintain in-house GLP/GCP-aligned preclinical laboratories, pilot manufacturing units, and automated GMP production lines, managing the entire lifecycle from raw material screening and validated HPLC/HPTLC assays to human clinical verification and finished formulation manufacturing.

Botanical variability is governed by weather, soil chemistry, harvest timing, and genetic variance. We mitigate this through our proprietary 3-point standardization protocol: First, we conduct origin and seasonal potency evaluations to secure raw materials solely from verified Daodi agricultural regions during peak harvest windows. Second, we establish chromatographic fingerprinting alongside multi-marker QAMS testing to monitor key active ingredients as well as total chemical profiles. Third, during our continuous extraction and purification processes, we adjust blending and separation parameters to ensure commercial batches consistently match tight specifications (typically ±0.5% to ±2% target assay).

Yes. We have developed 22 innovative natural medicines and secured 56 hospital preparation registrations within China. We support overseas clients by preparing complete Chemistry, Manufacturing, and Controls (CMC) dossiers, developing and validating analytical methodologies per ICH Q2 standards, conducting GLP animal safety studies (LD50, 90-day repeat dose subchronic toxicity, Ames bacterial reverse mutation, chromosome aberration assays), and managing Phase I through Phase IV clinical studies.

We operate exclusively on an entrusted research and contract manufacturing model under legally binding, bilingual Non-Disclosure and Non-Use Agreements (NDAs). MedGence treats all client parameters—including target ratios, unique solvent systems, and clinical indications—as trade secrets. Physical cleanrooms and synthesis suites can be isolated for client-specific batches, and access to research databases is restricted through strict role-based electronic authorizations.

Our quality testing laboratories are equipped with state-of-the-art instrumentation: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for heavy metals (meeting USP <232>/<233> and Ph. Eur. 2.4.27 limits), Triple Quadrupole GC-MS/MS and LC-MS/MS for 500+ pesticide residues (compliant with USP <561> and European Pharmacopoeia 2.8.13), Headspace Gas Chromatography (HS-GC-FID) for ICH Q3C residual solvents, and HPLC with fluorescence detection for mycotoxins and aflatoxins.

Our CDMO capabilities support both bulk botanical APIs and finished pharmaceutical/nutraceutical formulations:

Active Ingredient Deliverables: Supercritical botanical extracts, vacuum spray-dried powders, standardized crystalline isolates, concentrated aqueous/ethanolic liquids, and pure steam-distilled volatile oils.

Finished Dosage Forms: Oral liquids, hard gelatin/vegetarian capsules, high-potency softgels, precision-compressed tablets (film-coated or chewable), micro-granules, and effervescent soluble sachets.

For custom analytical method development or screening studies, pilot cohorts begin at 1 kg. Commercial-scale OEM production runs typically start at 25 kg to 100 kg for high-potency purified isolates, and 500 kg to multi-ton lots for standardized herbal extracts. Technical transfer and method re-validation require approximately 4 to 8 weeks, while standard repeat commercial production is dispatched within 15 to 20 working days.